ArticleCureus2025
Short-Term Renal Replacement Therapy Outcomes of Critically Ill Patients of Acute Kidney Injury and Acute on Chronic Kidney Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Renal Biomarkers and Albuminuria Predict Early Adverse Outcomes in Cardiorenal Syndrome Type 2.Medical sciences (Basel, Switzerland) · 2026Observational
- Use of Slow Low-Efficiency Dialysis in a Patient With Status Epilepticus Secondary to Herpes Simplex Encephalitis With Severe Acute Kidney Injury.Case reports in nephrology · 2026Article
- Sustained low-efficiency dialysis-an old method but possibly a new solution for environmental nephrology.Renal failure · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsSustained low-efficiency dialysis (SLED) is a cost-effective alternative to continuous renal replacement therapy (CRRT) in critically ill acute kidney injury (AKI) patients, in addition to intermittent hemodialysis (IHD) as a mode of renal replacement therapy (RRT) in such patients. This single-center, prospective, observational study aimed to assess the short-term outcomes of SLED and IHD in such patients. METHODOLOGY: Adult (>18 years) patients with AKI requiring dialysis were included from different ICUs of a tertiary care center. Patients were subjected to SLED or IHD according to the standard Kidney Disease: Improving Global Outcomes (KDIGO) 2012 criteria. Treatment duration and ultrafiltration rates were adjusted based on individual patient needs and hemodynamic stability was recorded. Dialysis-free survival, renal function recovery, and mortality rates at one month post discharge were analyzed among all RRT groups.
resultsOut of 128 ICU patients requiring dialysis, 78 underwent SLED, while 43 received IHD. Overall, the mean age was 44.53 years. Patients were predominantly male (53.7%), with common co-morbidities such as hypertension (21.5%) and diabetes mellitus (18.2%). Sepsis (59.2%), hypoperfusion (16.7%), and pregnancy-related AKI (14.16%) were the predominant causes of AKI. Indications for RRT initiation included refractory fluid overload, metabolic acidosis, and refractory hyperkalemia. Patients in the IHD group were relatively younger, had fewer comorbidities, and had more females than those in the SLED group. Thirty-day mortality in the SLED group was significantly higher than that in the IHD group (61.2% versus 20.9%, p < 0.05). Multivariate regression analysis identified vasopressin requirement, mechanical ventilation, and Sequential Organ Failure Assessment (SOFA) scores > 12 as predictors of mortality.
conclusionAlthough IHD is an option of RRT in reasonably stable patients, SLED is also a cost-effective option for hemodynamically unstable AKI patients, particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.